Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | ACACB | O00763 | 13/20 | 0.38 |
| ▸ | CTSD | P07339 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21669328 | 0.91 | KMT2A (0.40) | KMT2AALDH1A1LMNAMAPTHTT | |
| SCHEMBL21668913 | 0.88 | KMT2A (0.43) | KMT2AALDH1A1LMNAMAPTHTT | |
| SCHEMBL21669252 | 0.88 | KMT2A (0.38) | KMT2AALDH1A1LMNAMAPTHTT | |
| SCHEMBL21669257 | 0.88 | KLK5 (0.42) | KMT2AALDH1A1LMNAMAPTHTT | |
| SCHEMBL21669258 | 0.85 | KMT2A (0.40) | KMT2AALDH1A1LMNAMAPTHTT | |
| SCHEMBL21669234 | 0.84 | TRPM8 (0.48) | ALDH1A1CTSD | |
| SCHEMBL21669212 | 0.81 | KMT2A (0.43) | KMT2AALDH1A1LMNAMAPTHTT | |
| SCHEMBL21669237 | 0.81 | KMT2A (0.42) | KMT2AALDH1A1LMNAMAPTHTT | |
| SCHEMBL21669245 | 0.81 | KMT2A (0.41) | KMT2AALDH1A1LMNAMAPTHTT | |
| SCHEMBL21669312 | 0.79 | KMT2A (0.38) | KMT2AALDH1A1LMNAMAPTHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3829568-B1 | SULFOPROPANOIC ACID DERIVATIVES FOR TREATING NEURODEGENERATIVE DISORDERS | ALZHEON INC (US) | 2023-09-06 | — | — | EP | disclosed |
| US-20220087967-A1 | SULFOPROPANOIC ACID DERIVATIVES FOR TREATING NEURODEGENERATIVE DISORDERS | ALZHEON, INC. | 2022-03-24 | — | — | US | disclosed |
| WO-2020028348-A1 | SULFOPROPANOIC ACID DERIVATIVES FOR TREATING NEURODEGENERATIVE DISORDERS | ALZHEON, INC. (US) | 2020-02-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220087967-A1 | SULFOPROPANOIC ACID DERIVATIVES FOR TREATING NEURODEGENERATIVE DISORDERS | PSEN1, APP, PSEN2 | KMT2A 3892/4885ALDH1A1 591/4885LMNA 4021/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.